Skip to content
Adbry, Adtralza(tralokinumab)
Adbry, Adtralza (tralokinumab) is an antibody pharmaceutical. Tralokinumab was first approved as Adtralza on 2021-06-17. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Adbry
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tralokinumab
Tradename
Proper name
Company
Number
Date
Products
Adbrytralokinumab-ldrmLEO Pharma A/SN-761180 RX2021-12-27
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
adbryBiologic Licensing Application2021-12-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atopic dermatitisEFO_0000274D003876L20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AH: Agents for dermatitis, excluding corticosteroids
— D11AH07: Tralokinumab
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L20159—115
AsthmaD001249EFO_0000270J45443——11
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Idiopathic pulmonary fibrosisD054990J84.112—2———2
Alopecia areataD000506EFO_0004192L63—1———1
Ulcerative colitisD003093EFO_0000729K51—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4————4
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRALOKINUMAB
INNtralokinumab
Description
Tralokinumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)TRALOKINUMAB
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB5L6Y
CAS-ID1044515-88-9
RxCUI—
ChEMBL IDCHEMBL1743081
ChEBI ID—
PubChem CID—
DrugBankDB12169
UNII IDGK1LYB375A (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Tralokinumab - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 803 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3 adverse events reported
View more details